Characterization of Extracellular Vesicles in Breast Cancer Patients

This is a prospective, observational, monocentric and no profit study. The study involves the analysis of plasma from patients with breast cancer in order to quantify and characterize tumor-derived EVs at specific disease stages.

The enrollment of consecutive patients affected by BC referring to an EUSOMA-accredited Breast Unit is planned.

The patients will be divided into three pre-planned groups, as follows:

Population 1: patients diagnosed with early breast cancer patients (stage I-III) with indication to curative surgery.

Population 2: a control group made of sex- and age-matched healthy volunteers, not affected by cancer or chronic diseases.

Population 3: patients with metastatic breast cancer diagnosis. For each patient a blood sample will be collected and plasma will be isolated. A new SiMoA assay based on the use of anti-CD63 and anti-CD9 antibodies, two well known protein markers of EVs, will be used to capture and quantify EVs directly from plasma without requiring any prior sample processing.

The study will be conducted following the International Conference on Harmonization [ICH] Good Clinical Practice [GCP] guidelines. The Ethical Committee of ICS Maugeri authorized the study as protocol 2490/2020.

Inclusion criteria

• Signing of a specific informed consent for participation to the study
• Female sex

Population 1:

• Diagnosis of early breast cancer;
• Indication for surgery after multidisciplinary discussion.

Population 2:

• Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment.

Population 3:

• Diagnosis of metastatic breast cancer confirmed by cytological/histological examination or by imaging;
• Indication to chemotherapy.

Exclusion criteria

Population 1:

• Presence of distant metastases
• Synchronous presence of a different tumor
• Indication to neoadjuvant chemotherapy

Population 2:

• Diagnosis of breast cancer
• Synchronous presence of a different tumor or chronic disease

Population 3:

• Patients who are unfit for systemic chemotherapy treatment